Obese and non-obese polycystic ovarian syndrome: comparison of clinical, metabolic, hormonal parameter and their differential response to oral ovulation induction drugs
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20254271Keywords:
Infertility, Polycystic ovarian syndrome, Obesity, Ovulation inductionAbstract
Background: Polycystic ovarian syndrome (PCOS) is a complex disorder characterized by hyperandrogenism, menstrual irregularities, and polycystic ovaries. The present study compared obese and non-obese PCOS patients in terms of clinical, metabolic, and hormonal parameters, as well as their response to oral ovulation induction drugs.
Methods: This study was conducted in the Department of Obstetrics and Gynaecology, AIMSR Bathinda, over one year after approval from the Institutional Ethics Committee. Women with PCOS presenting with infertility were enrolled. Patients were categorized into obese and non-obese groups, and their clinical, metabolic, and hormonal profiles were compared. Data were recorded in Microsoft Excel and analysed using SPSS software.
Results: The mean age was 25.3 years in the obese group and 26.1 years in the non-obese group. Mean fasting insulin levels were higher in obese patients (25.1 µIU/ml) compared to non-obese (15.9 µIU/ml). Similarly, insulin resistance and HOMA-IR values were significantly greater in the obese group. Mean testosterone levels were slightly higher in obese patients (58.3 ng/dl vs. 55.4 ng/dl). Conception rates following oral ovulation induction were significantly lower in obese women (30.6%) than in non-obese women (76.3%).
Conclusions: Obese women with PCOS are at higher risk of metabolic derangements and exhibit poorer responsiveness to ovulation induction therapy. Early identification and targeted weight management strategies may not only prevent adverse outcomes but also improve fertility outcomes in this population.
References
Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P T. 2013;38(6):336-55.
Bharali MD, Rajendran R, Goswami J, Singal K, Rajendran V. Prevalence of polycystic ovarian syndrome in India: a systematic review and meta-analysis. Cureus. 2022;14(12):e32351.
Wu Q, Gao J, Bai D, Yang Z, Liao Q. The prevalence of polycystic ovarian syndrome in Chinese women: a meta-analysis. Ann Palliat Med. 2021;10:74-87.
Makhija N, Tayade S, Toshniwal S, Tilva H. Clinico-metabolic profile in lean versus obese polycystic ovarian syndrome women. Cureus. 2023;15(4):e37809.
Rich-Edwards JW, Spiegelman D, Garland M, Hertzmark E, Hunter DJ, Colditz GA, et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiol. 2002;13(2):184-90.
Douchi T, Ijuin H, Nakamura S, Oki T, Yamamoto S, Nagata Y. Body fat distribution in women with polycystic ovary syndrome. Obstet Gynecol. 1995;86(4):516-9.
Athaullah N, Proctor M, Johnson NP. Oral versus injectable ovulation induction agents for unexplained subfertility. Coch Data Syst Rev. 2002;2002(3):CD003052.
Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Obese and non‑obese polycystic ovarian syndrome: Comparison of clinical, metabolic, hormonal parameters, and their differential response to clomiphene. Indian J Endocr Metab. 2019;23(2):257-62.
Akshaya S, Bhattacharya R. Comparative study of clinical profile of lean and obese polycystic ovary syndrome women. Int J Reprod Contracept Obstet Gynecol. 2016;5(8):2530-3.
Sam S. Obesity and polycystic ovary syndrome. Obes Manag. 2007;3(2):69-73.
Makhija N, Tayade S, Toshniwal S, Tilva H. Clinico-metabolic profile in lean versus obese polycystic ovarian syndrome women. Cureus. 2023;15(4):e37809.
Kim MJ, Lim NK, Choi YM, Kim JJ, Hwang KR, Chae SJ, et al. Prevalence of metabolic syndrome is higher among non-obese PCOS women with hyperandrogenism and menstrual irregularity in Korea. PLoS One. 2014;9(6):e99252.
Downloads
Published
How to Cite
Issue
Section
